The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to ...
Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...
Presented at this week’s European Congress on Obesity, the two studies also demonstrate that Novo Nordisk’s Wegovy ...
Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, ...
The data could go some way to convince insurers and governments to reimburse Wegovy. Read more at straitstimes.com.
Researchers highlighted on Monday that certain genes may help identify patients with obesity who are most likely to respond ...
A Novo spokesperson said in a statement to Reuters that the new analysis “demonstrates for the first time the benefits of ...
The study found that the majority of people on Wegovy lost weight, on average 10% of their body weight, in the first 15 ...
Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.
The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to cover the costly drug. Patients taking Novo Nordisk's obesity drug Wegovy ...